112 related articles for article (PubMed ID: 33998784)
1. Hand-Foot Skin Reaction Secondary to Sunitinib in a Patient With Metastatic Clear Cell Renal Cell Carcinoma.
Férez-Blando K; Castro-Alonso F; Domínguez-Cherit J; Bourlon MT
Oncology (Williston Park); 2021 May; 35(5):272-276. PubMed ID: 33998784
[TBL] [Abstract][Full Text] [Related]
2. Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma.
Kucharz J; Budnik M; Dumnicka P; Pastuszczak M; Kuśnierz-Cabala B; Demkow T; Popko K; Wiechno P
Adv Exp Med Biol; 2019; 1133():35-40. PubMed ID: 30701441
[TBL] [Abstract][Full Text] [Related]
3. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Topical Urea for Secondary Prophylaxis of Hand Foot Skin Reaction in Renal Cell Cancer Patients on Sunitinib Therapy.
Naeem SS; Gupta P; Sahoo RK; Kumar VL; Velpandian T; Singh A; Batra A; Pramanik R; Rastogi S; Srivastava S
Clin Genitourin Cancer; 2024 Jun; 22(3):102073. PubMed ID: 38626661
[TBL] [Abstract][Full Text] [Related]
5. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
Teo YL; Chong XJ; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
Cancer Chemother Pharmacol; 2014 Feb; 73(2):381-8. PubMed ID: 24306119
[TBL] [Abstract][Full Text] [Related]
6. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Chu D; Lacouture ME; Weiner E; Wu S
Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
8. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K
Tumori; 2015; 101(5):555-9. PubMed ID: 26045121
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
10. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
[TBL] [Abstract][Full Text] [Related]
12. Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma.
Ballardini P; Margutti G; Aliberti C; Manfredini R
Clin Drug Investig; 2009; 29(7):487-490. PubMed ID: 19499966
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Sunitinib Alternative Prescription Schedules in Metastatic Kidney Cancer: A Study of 10 Cases.
Diallo H; Mhamdi HA; Elouarzazi S; Fadli M; Belbaraka R
Gulf J Oncolog; 2018 Jan; 1(26):33-36. PubMed ID: 29607820
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
Ohtsuka T
J Dermatol; 2012 Nov; 39(11):943-4. PubMed ID: 22257303
[No Abstract] [Full Text] [Related]
15. [Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma].
Choi SW; Lee JM; Kim DG; Noh MH
Korean J Gastroenterol; 2020 Feb; 75(2):103-107. PubMed ID: 32098465
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).
Yamamoto K; Nishiyama S; Kunisada M; Iida M; Ito T; Ioroi T; Makimoto H; Omura T; Harada K; Fujisawa M; Nishigori C; Yano I
Oncologist; 2022 May; 27(5):e384-e392. PubMed ID: 35285503
[TBL] [Abstract][Full Text] [Related]
17. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma.
Najjar YG; Mittal K; Elson P; Wood L; Garcia JA; Dreicer R; Rini BI
Eur J Cancer; 2014 Apr; 50(6):1084-9. PubMed ID: 24559686
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
